Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy

被引:9
作者
El Beshlawy, Amal [1 ]
Murugesan, Vagishwari [2 ]
Mistry, Pramod Kumar [3 ]
Eid, Khaled [1 ]
机构
[1] Cairo Univ, Dept Pediat, Pediat Hematol, Giza, Egypt
[2] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA
[3] Yale Univ, Internal Med & Pediat, Sch Med, 333 Cedar St,LMP 1080,POB 208019, New Haven, CT 06520 USA
关键词
Gaucher disease; Hepatopulmonary syndrome; Enzyme replacement therapy; Pulmonary complications; PULMONARY-HYPERTENSION; PHENOTYPE; DETERMINANTS; ASSOCIATION; CELLS;
D O I
10.1016/j.ymgmr.2019.100490
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Advanced liver disease complicated by hepatopulmonary syndrome is a recognized complication of Gaucher disease. Macrophage-targeted, recombinant enzyme replacement therapy is effective in reversing clinical manifestations attributed to the accumulation of glycolipid-laden macrophages but it is not known whether advanced fibrotic features of the disease can be ameliorated. We describe a splenectomized patient with Gaucher disease who developed massive hepatomegaly, cirrhosis of the liver and life-threatening hepatopulmonary syndrome. Treatment with Imiglucerase enzyme replacement therapy resulted in dramatic reversal of hepatopulmonary syndrome and liver disease. Our report suggests that Gaucher disease pathology involving advanced fibrosis and life-threatening complications can be reversed by imiglucerase enzyme therapy. Synopsis: Effect of imiglucerase enzyme replacement therapy on Hepatopulmonary Syndrome in Gaucher Disease.
引用
收藏
页数:4
相关论文
共 24 条
[1]   Liver Fibrosis in Type I Gaucher Disease: Magnetic Resonance Imaging, Transient Elastography and Parameters of Iron Storage [J].
Bohte, Anneloes E. ;
van Dussen, Laura ;
Akkerman, Erik M. ;
Nederveen, Aart J. ;
Sinkus, Ralph ;
Jansen, Peter L. M. ;
Stoker, Jaap ;
Hollak, Carla E. M. .
PLOS ONE, 2013, 8 (03)
[2]   Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages [J].
Boven, LA ;
van Meurs, M ;
Boot, RG ;
Mehta, A ;
Boon, L ;
Aerts, JM ;
Laman, JD .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2004, 122 (03) :359-369
[3]   Pulmonary hypertension developing after alglucerase therapy in two patients with type 1 Gaucher disease complicated by the hepatopulmonary syndrome [J].
Dawson, A ;
Elias, DJ ;
Rubenson, D ;
Bartz, SH ;
Garver, PR ;
Kay, AC ;
Bloor, CM ;
Beutler, E .
ANNALS OF INTERNAL MEDICINE, 1996, 125 (11) :901-904
[4]   Increased incidence of cancer in adult Gaucher disease in Western Europe [J].
de Fost, M ;
vom Dahl, S ;
Weverling, GJ ;
Brill, N ;
Brett, S ;
Häussinger, D ;
Hollak, CEM .
BLOOD CELLS MOLECULES AND DISEASES, 2006, 36 (01) :53-58
[5]  
Harats D, 1997, ACTA HAEMATOL-BASEL, V98, P47
[6]   Pulmonary function abnormalities in type I Gaucher disease [J].
Kerem, E ;
Elstein, D ;
Abrahamov, A ;
Ziv, YB ;
HadasHalpern, I ;
Melzer, E ;
Cahan, C ;
Branski, D ;
Zimran, A .
EUROPEAN RESPIRATORY JOURNAL, 1996, 9 (02) :340-345
[7]   Massive hepatic fibrosis in Gaucher's disease: Clinicopathological and radiological features [J].
Lachmann, RH ;
Wight, DGD ;
Lomas, DJ ;
Fisher, NC ;
Schofield, JP ;
Elias, E ;
Cox, TM .
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 2000, 93 (04) :237-244
[8]  
Lee R., 1988, FREQUENCY TYPE LUNG, P21201
[9]  
Lee R E, 1982, Prog Clin Biol Res, V95, P177
[10]   Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long-term outcomes of therapy [J].
Lo, Sarah Michelman ;
Liu, Jun ;
Chen, F. ;
Pastores, G. M. ;
Knowles, J. ;
Boxer, M. ;
Aleck, Kirk ;
Mistry, Pramod K. .
JOURNAL OF INHERITED METABOLIC DISEASE, 2011, 34 (03) :643-650